Gilead Sciences Balance Sheet Health
Financial Health criteria checks 4/6
Gilead Sciences has a total shareholder equity of $22.7B and total debt of $25.0B, which brings its debt-to-equity ratio to 109.8%. Its total assets and total liabilities are $62.1B and $39.4B respectively. Gilead Sciences's EBIT is $9.8B making its interest coverage ratio 17.3. It has cash and short-term investments of $8.4B.
Key information
109.8%
Debt to equity ratio
US$24.99b
Debt
Interest coverage ratio | 17.3x |
Cash | US$8.35b |
Equity | US$22.75b |
Total liabilities | US$39.38b |
Total assets | US$62.13b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: GIS's short term assets ($16.1B) exceed its short term liabilities ($11.3B).
Long Term Liabilities: GIS's short term assets ($16.1B) do not cover its long term liabilities ($28.1B).
Debt to Equity History and Analysis
Debt Level: GIS's net debt to equity ratio (73.1%) is considered high.
Reducing Debt: GIS's debt to equity ratio has reduced from 126.9% to 109.8% over the past 5 years.
Debt Coverage: GIS's debt is well covered by operating cash flow (32%).
Interest Coverage: GIS's interest payments on its debt are well covered by EBIT (17.3x coverage).